Sunday, 20 September 2026European Markets

ORAPI Stock Jumps By 28% In The Last 21 Sessions

Loading stream...

(vianews) - shares of orapi (cac 40: orap.pa) rose by a staggering 28.64% in 21 sessions from €4.4 to €5.66 at 17:06 est on thursday, following the last session's upward trend. cac 40 is rising 0.91% to €7,399.92, after four sequential sessions in a row of gains.

orapi's last close was €5.68, 0.35% under its 52-week high of €5.70.

about orapi

orapi sa, together with its subsidiaries, designs, manufactures, and sells products and solutions for hygiene and industrial maintenance worldwide. the company's products consist of cleaners, such as degreasers, disinfectants, hygiene and decontamination products, wiping pads, soaps, etc.; and lubricants, include greases and oils; and glues and adhesives, such as cyanoacrylates, anaerobes, and neoprenes. it also offers various wadding products, which include toilet papers and hand towels; waste bags; and personal protective equipment, such as gloves, masks, etc. the company operates under the hexotol, orapi process, orapi hygiène, proven, orapi technic, and transnet brands. it serves customers in various sectors, such as industry, transport, leisure, collectivities, and health. the company was founded in 1968 and is based in saint-vulbas, france.

earnings per share

as for profitability, orapi has a trailing twelve months eps of €0.12.

pe ratio

orapi has a trailing twelve months price to earnings ratio of 47.17. meaning, the purchaser of the share is investing €47.17 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 1.53%.

more news about orapi (orap.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Boom Hits a Fork: Slowdown Calls Clash with Capex Confidence as Markets Get Nervous
Dario Amodei's repeated calls for a global slowdown in frontier AI development, echoed by Microsoft's new humanist AI code of conduct and FTC antitrust caution, are being publicly rejected by Nvidia and Meta leadership even as hyperscaler spending draws fresh skeptical scrutiny (Wachter's analysis, Burry-style overbuilding worries) and weak guidance from Adobe and a post-slowdown-comment selloff in GE Vernova signal investor jitters. Meanwhile wealth and security effects of the AI race keep compounding — Zhang Yiming's fortune surging on AI-driven ByteDance value, a Chinese hacking firm weaponizing AI against stolen government secrets, and low-quality AI-generated products (an AI sitcom, a spam-flooding agent platform) fueling backlash even as adoption races ahead.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,982
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,982 facts checked against source5,299 source documents archived
Query this data → isubstrate.com